Treatments for Brain Metastases With Poor Prognostic Factors
- Conditions
- Brain Metastases
- Interventions
- Procedure: neurosurgical resection
- Registration Number
- NCT05609162
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are:
* What kind of local treatment provides a survival benefit for patients with poor prognostic factors?
* What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors?
* Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors?
Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 2000
- Evidence of pathological diagnosis of primary tumor;
- Brain metastases confirmed by enhanced magnetic resonance imaging;
- Complete clinical information
- Survival time less than 30 days;
- If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery;
- Incomplete clinical data;
- Patients with 2 or more types of tumors.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description systemic treatment group vs local treatment+systemic treatment group neurosurgical resection Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group local treatment+systemic treatment group vs non-local treatment+systemic treatment group neurosurgical resection Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group local treatment group vs systemic treatment group neurosurgical resection Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group local treatment group vs local treatment+systemic treatment group neurosurgical resection Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group local treatment group vs non-local treatment group neurosurgical resection Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
- Primary Outcome Measures
Name Time Method OS From date of first follow-up until the date of documented death from any cause, assessed up to 120 months Overall survival time
- Secondary Outcome Measures
Name Time Method PFS From date of first follow-up until the date of first documented progression, assessed up to 120 months Progression-free survival time
Trial Locations
- Locations (1)
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China